Wikipedia

Odapipam

(Redirected from NNC 10756)

Odapipam (INNTooltip International Nonproprietary Name; developmental code names NNC 01-0756, NNC-756, NO-756) is a selective D1 receptor antagonist of the benzazepine group which was investigated as a potential antipsychotic but was never marketed.[1][2]

Odapipam
Clinical data
Other namesNNC 01-0756; NNC-01-0756; NNC-010756; NNC010756; NNC01-0756; NNC-756; NNC756; NNC 0756; NNC0756; NO-756; NO756
Drug classDopamine D1 receptor antagonist
Identifiers
  • (5S)-8-chloro-5-(2,3-dihydro-1-benzofuran-7-yl)-3-methyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H20ClNO2
Molar mass329.82 g·mol−1
3D model (JSmol)
  • CN1CCC2=CC(=C(C=C2[C@H](C1)C3=CC=CC4=C3OCC4)O)Cl
  • InChI=1S/C19H20ClNO2/c1-21-7-5-13-9-17(20)18(22)10-15(13)16(11-21)14-4-2-3-12-6-8-23-19(12)14/h2-4,9-10,16,22H,5-8,11H2,1H3/t16-/m1/s1
  • Key:SKMVRXPBCSTNKE-MRXNPFEDSA-N

It has more than 5,000-fold selectivity for the dopamine D1 receptor (Ki = 0.17 nM) over the dopamine D2 receptor (Ki = 942 nM).[3] Its affinities for other dopamine receptors, such as the dopamine D5 receptor, were not reported.[3][4] In addition to the dopamine D1 receptor, odapipam showed relatively high affinity for the serotonin 5-HT2 receptor (Ki = 4.5 nM; 26-fold lower than for the D1 receptor).[4]

The drug was first described in the scientific literature by 1988.[4][5]

See also

edit

References

edit
  1. ^ Shen WW (1999). "A history of antipsychotic drug development". Compr Psychiatry. 40 (6): 407–414. doi:10.1016/s0010-440x(99)90082-2. PMID 10579370.407-414&rft.date=1999&rft_id=info:doi/10.1016/s0010-440x(99)90082-2&rft_id=info:pmid/10579370&rft.aulast=Shen&rft.aufirst=WW&rfr_id=info:sid/en.wikipedia.org:Odapipam" class="Z3988">
  2. ^ Seamans JK, Yang CR (September 2004). "The principal features and mechanisms of dopamine modulation in the prefrontal cortex". Prog Neurobiol. 74 (1): 1–58. doi:10.1016/j.pneurobio.2004.05.006. PMID 15381316.1-58&rft.date=2004-09&rft_id=info:doi/10.1016/j.pneurobio.2004.05.006&rft_id=info:pmid/15381316&rft.aulast=Seamans&rft.aufirst=JK&rft.au=Yang, CR&rfr_id=info:sid/en.wikipedia.org:Odapipam" class="Z3988">
  3. ^ a b Neumann J, Hofmann B, Dhein S, Gergs U (March 2023). "Role of Dopamine in the Heart in Health and Disease". Int J Mol Sci. 24 (5): 5042. doi:10.3390/ijms24055042. PMC 10003060. PMID 36902474.
  4. ^ a b c Andersen PH, Grønvald FC, Hohlweg R, Hansen LB, Guddal E, Braestrup C, Nielsen EB (August 1992). "NNC-112, NNC-687 and NNC-756, new selective and highly potent dopamine D1 receptor antagonists". Eur J Pharmacol. 219 (1): 45–52. doi:10.1016/0014-2999(92)90578-r. PMID 1397049.45-52&rft.date=1992-08&rft_id=info:doi/10.1016/0014-2999(92)90578-r&rft_id=info:pmid/1397049&rft.aulast=Andersen&rft.aufirst=PH&rft.au=Grønvald, FC&rft.au=Hohlweg, R&rft.au=Hansen, LB&rft.au=Guddal, E&rft.au=Braestrup, C&rft.au=Nielsen, EB&rfr_id=info:sid/en.wikipedia.org:Odapipam" class="Z3988">
  5. ^ Waddington JL (January 1989). "Functional interactions between D-1 and D-2 dopamine receptor systems: their role in the regulation of psychomotor behaviour, putative mechanisms, and clinical relevance". J Psychopharmacol. 3 (2): 54–63. doi:10.1177/026988118900300202. PMID 22156499.54-63&rft.date=1989-01&rft_id=info:doi/10.1177/026988118900300202&rft_id=info:pmid/22156499&rft.aulast=Waddington&rft.aufirst=JL&rfr_id=info:sid/en.wikipedia.org:Odapipam" class="Z3988">


 

This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Odapipam&oldid=1252743328"